The new findings are the first to describe distributions and perturbations of low-density granulocyte and normal-density ...

Saeed Sadeghi, MD, discusses the findings on transfusion independence achieved with treatment for patients with low-risk ...

The rate of cGVHD-free survival was 78% at 1 year in patients who received Orca-T compared with 38% among patients who ...

Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...

Geron Corp's Rytelo launch & robust pipeline offer a compelling investment opportunity, despite stock challenges. Click here ...

VCAR33 clinical data update planned for first half of 2025 and trem-cel + Mylotarg clinical data update planned for second ...

Darzalex and Revlimid maintenance resulted in superior outcomes versus Revlimid alone following autologous stem cell ...

Increased mixed chimerism, as detected by AlloHeme, could predict post-transplant relapse “with a high degree of accuracy,” said Monzr M. Al Malki, MD.

myelodyplastic syndromes (MDS), having met primary and key secondary endpoints. The COMMANDS study (NCT03682536) - a phase 3 open-label, randomised trial to evaluate the efficacy and safety of ...

GLP-1 RA use linked to lower risks for myelodysplastic syndromes, myeloproliferative neoplasms compared with metformin ...

TURKU, FI / ACCESS Newswire / March 20, 2025 /Faron Pharmaceuticals (HEL:FARON)(AIM:FARN) Shareholders' Nomination Board updates its recommendation on the number of Board members to be elected and the ...

Orca-T improved 1-year survival without severe graft-vs-host disease compared with standard transplant in the Precision-T ...